AVnovum is developing a new class of antimicrobial therapy, AVpeptides, that maintain healthy fungal microbiomes by preventing virulence and infection. AVpeptides work through mechanisms that specifically target virulent but not health-promoting microbes. AVnovum is driven by a diverse team of research scientists and advisors from the University of Chicago Medical Center with scientific, entrepreneurial, and business backgrounds, who are dedicated to improving patient outcomes in those with diabetes, immunodeficiencies, and immunosuppression. The company was awarded up to to $150,000 by the UChicago Innovation Fund to further the development of a new class of antimicrobial peptides that maintain healthy fungal microbiomes by preventing virulence and infection.
- Founded by Eugene Chang, MD, Katherine Harris, PhhD, Myles Minter, PhD, and Joseph Pierre, PhD
- Awarded up to $150,000 at the Spring 2017 George Shultz Innovation Fund Finals
- Headquartered in Chicago, IL